Polio Epidemiology: Strategies and Challenges for Polio Eradication Post the COVID-19 Pandemic.

Publication date: Nov 26, 2024

The Global Polio Eradication Initiative (GPEI), launched in 1988, has successfully reduced wild poliovirus (WPV) cases by over 99. 9%, with WPV type 2 and WPV3 declared eradicated in 2015 and 2019, respectively. However, as of 2024, WPV1 remains endemic in Afghanistan and Pakistan. Since 2000, outbreaks of circulating virus derived of polio vaccines (cVDPVs) have emerged in multiple regions, primary driven by low vaccine coverage rates (VCRs). The COVID-19 pandemic disrupted routine immunization, resulting in millions of unvaccinated children, and leaving many countries vulnerable to both WPV1 and cVDPVs outbreaks. This paper reviews the epidemiological landscape of poliomyelitis post the COVID-19 pandemic, and the strategies and challenges to achieve the global polio eradication.

Open Access PDF

Concepts Keywords
Afghanistan epidemiology
Basel polio eradication
Eradication poliomyelitis
Poliovirus surveillance
vaccine coverage

Semantics

Type Source Name
disease MESH Polio
disease MESH COVID-19 Pandemic
drug DRUGBANK Coenzyme M
disease MESH acute flaccid paralysis
drug DRUGBANK Spinosad
disease MESH breakthrough infections
disease MESH paralysis
disease MESH infections
disease IDO cell
drug DRUGBANK Pentetic acid
disease MESH pertussis
pathway KEGG Pertussis
disease IDO country
disease MESH Emergency
disease MESH scar
drug DRUGBANK Methyl isocyanate
disease MESH seroconversion
disease MESH measles
pathway KEGG Measles
drug DRUGBANK Water
disease MESH ramp
disease IDO production
disease IDO process
disease MESH diphtheria
disease MESH tetanus
disease MESH Hepatitis
pathway REACTOME Release
disease IDO immunodeficiency
drug DRUGBANK Guanosine
disease MESH Severe Combined Immune Deficiency
disease IDO history

Original Article

(Visited 1 times, 1 visits today)